Britain and America have concluded a landmark trade agreement that will keep zero levies on British medicine products going into the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that duties on these key goods will remain at zero for a timeframe of 36 months.
This deal follows previous threats to significantly raise import taxes on branded drug products, with figures mentioned reaching one hundred percent.
"This agreement between the UK reinforces the international landscape for innovative medicines and introduces much-needed equity to transatlantic pharmaceutical trade," a release noted.
Economic Importance
Pharmaceuticals are one of the Britain's biggest export categories to the America, which is by far the largest destination for leading companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months to the end of September, the UK shipped pharmaceutical products worth billions to the US. This amount made up 17.4% of all goods exports in that period.
"This guarantee secures employment, boosts funding and facilitates the UK to establish itself as a worldwide center for medical research," a government official stated.
Specific UK Commitments
The deal involves several key changes from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Previously, repayments exceeded twenty percent.
Recent Tensions
The pact takes place against a ongoing dispute between the sector and the UK government over drug pricing and NHS adoption.
These tensions were intensified by assertions that American customers were paying a premium for the same drugs than people in the UK and Europe.
Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while major expansions have been pledged toward US facilities.
One official publicly accepted that the NHS must spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
